All In Biotech

Drug Trial Radar · NCT00671307

Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels

Phase 1b Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Infusion Trial of the Pharmacokinetics of Rhu-pGelsolin in Patients With Decreased Natural Gelsolin Levels

Last checked: Nov 20, 2026Latest source record: Sep 29, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Planned (sponsor's estimate)

Start

Mar 2008

Primary completion

Mar 2010

Study completion May 2010

Sponsor

Lead sponsor
Critical Biologics CorporationIndustry
Sponsor type
Industry
First posted
May 5, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to assess the pharmacokinetics and safety of an infusion of a single dose of recombinant plasma gelsolin (rhu-pGelsolin) when given to patients admitted to the Intensive Care Unit with documented low levels of natural gelsolin. It is believed that this drug will raise the gelsolin levels in these patients and decrease the probability that they will develop complications from their underlying disease such as organ system failure or death.

Conditions

  • Low Gelsolin
  • Trauma
  • Infection
  • Burns

Interventions

  • rhu-pGelsolinDrug

    IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour

  • PlaceboDrug

    Vehicle control given as IV infusion over 1 hour

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics of plasma gelsolinTime frame: 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Queen Mary Hospital; University of Hong Kong

    Hong Kong, SAR, Hong Kong

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.